174258-32-3

Upstream product

• 159017-85-3 3-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]benzaldehyde 
• 174258-31-2 [3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methanol 

Downstream Products

• 250602-86-9 N-{3-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]benzyloxy}phtalimide 
• 250602-87-0 3-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]benzyloxyamine 
• 250601-73-1 methyl (E)-4-{3-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]benzyloxyimino}-4-phenylbutyrate 
• 250601-74-2 ethyl (E)-6-{3-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]benzyloxyimino}-6-phenylhexanoate 
• 1065334-73-7 3-methyl-1-(3-((5-methyl-2-phenyloxazol-4-yl)methoxy)benzyl)piperidine-3-carboxylic acid ethyl ester 

Relevant academic research and scientific papers

Studies on non-thiazolidinedione antidiabetic Agents. 2. Novel oxyiminoalkanoic acid derivatives as potent glucose and lipid lowering agents

We previously reported that (Z)-2-{4-[(5-methyl-2-phenyl-1,3-oxazol-4-yl) methoxy]benzyloxyimino}-2-(4-phenoxyphenyl)acetic acid (3) showed potent glucose and lipid lowering effects in genetically obese and diabetic mice, KKA y. This compound a

Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity

This invention provides a novel oxyiminoalkanoic acid derivative which has excellent hypoglycemic and hypolipidemic actions and which is used for the treatment of diabetes mellitus, hyperlipemia, insulin insensitivity, insulin resistance and impaired glucose tolerance.